2025 · 2nd Quarter (Apr 1 - June 30)

VERTEX PHARMACEUTICALS INCORPORATED

Filed by AVENUE SOLUTIONS.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 21, 2025
Income: $60,000.00
Expenses: Not reported
Registrant: AVENUE SOLUTIONS
Client: VERTEX PHARMACEUTICALS INCORPORATED
Filing UUID: 504f5e9f-2f94-42d8-ab37-c1cf507a66b8
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; H.R. 1672, Maintaining Investments in New Innovation Act; Biosimilars Access and Affordability Act; H.R. 2484, Seniors Access to Critical Medications Act; H.R. 946/S. 1862, ORPHAN Cures Act; Issues related to PBM reform; Issues related to Most Favored Nation (MFN) drug pricing proposal

Literal federal measure citations: H.R. 1227, S. 475, H.R. 1672, H.R. 2484, H.R. 946, S. 1862

HCR · Health Issues

Monitor issues related to 340b; Health care issues in H.R. 1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21)

Literal federal measure citations: H.R. 1, H. Con. Res. 14

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.